Back to discover
Drug

Osunprotafib

Research stage
Emerging research
RxNorm2721346ChEMBLCHEMBL5095164UNII82TTG6WR6B
1
Research papers
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Osunprotafib
RxNorm CUI
2721346
ChEMBL ID
CHEMBL5095164
UNII
82TTG6WR6B

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Major research themes6
Immunotherapy1Naphthalenes1Neoplasms1Protein Tyrosine Phosphatase, Non-Receptor Type 11Protein Tyrosine Phosphatase, Non-Receptor Type 21Thiadiazoles1
Journals, researchers & institutions
Top journals
  • Nature1
Leading researchers
  • Avila OI1
  • Backus C1
  • Balon TM1
  • Baumgartner CK1
  • Beauregard C1
  • Boghossian A1
  • Bulic M1
  • Chen A1
Leading institutions
free-text, unnormalised
  • Broad Institute of MIT and Harvard1
  • Center for Cancer Research and Department of Medicine1
  • Dana-Farber Cancer Institute1
  • Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology1
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature